News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Company Profile For Acumen Pharmaceuticals Inc.


10/19/2005 5:09:42 PM

(BUSINESS WIRE)--Acumen Pharmaceuticals Inc. (www.acumenpharm.com) is a venture-backed, pre-clinical biotech company, focused on developing the first effective therapeutics and diagnostics for Alzheimer's disease and other memory-related disorders. Founded in 1996, Acumen owns or has licensed the critical patents underlying the ADDL mechanism now widely believed to cause Alzheimer's disease. In addition to an ELISA-based diagnostic, Acumen has three small molecule programs to stop ADDL-related diseases. NeuroVentures LLC and the Biotech Value Fund have made a seed investment in the Company.

Company: Acumen Pharmaceuticals, Inc.

Headquarters Address: 1309 Evergreen Court Glenview, IL 60025

Main Telephone: 415-281-1392

Type of Organization: Private

Industry: Health: Biotechnology

Key Executives: CEO: David Summa CSO: Grant Krafft

President Contact: David Summa Phone: 415-281-1392 Email: info@acumenpharm.com

Chief Science Officer Contact: Grant Krafft Phone: 847-729-6687 Email: info@acumenpharm.com

Contact: Acumen Pharmaceuticals, Inc.

Source: Acumen Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES